Drug Profile
Pertussis acellular vaccine - GlaxoSmithKline
Latest Information Update: 28 Apr 2011
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Class Bacterial vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Pertussis
Most Recent Events
- 23 Jan 2001 SmithKline Beecham has merged with Glaxo Wellcome to form GlaxoSmithKline
- 24 Oct 2000 PowderJect Pharmaceuticals has acquired Medeva's vaccines business from Celltech and renamed it as Evans Vaccines
- 02 Feb 2000 Medeva has been merged into Celltech Chiroscience, which is now called Celltech Group